Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 10,545 matching trials from the live ClinicalTrials.gov search.
Filters: Cincinnati, Ohio Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

NCT02603120
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
61
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

Development of a Multi-faceted Cognitive Training Program for Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01352468
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Multifaceted cognitive training
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

NCT01725191
View directory record Official record
Conditions
Childhood Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Tivantinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Months to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE)

NCT02250820
View directory record Official record
Conditions
Heart Disease
Interventions
Dexmedetomidine, Pentobarbital, Oral Placebo, Nasal Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months to 24 Months
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

NCT01926782
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Statin
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 31, 2026, 5:25 PM EDT
Terminated Phase 3 Interventional

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

NCT01168791
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Palifosfamide-Tris, doxorubicin, Placebo
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 5:25 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

NCT05540860
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
4 Years to 9 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

NCT03877224
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 150 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
25
States / cities
Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 31, 2026, 5:25 PM EDT
Completed No phase listed Observational

Genetic Collection Protocol

NCT05272319
View directory record Official record
Conditions
Liver Diseases
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
24 Hours to 25 Years
Enrollment
171 participants
Timeline
2022 – 2026
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 3 Interventional

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

NCT00039000
View directory record Official record
Conditions
Malignant Melanoma
Interventions
HSPPC-96 or Oncophage
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody

NCT02069899
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Grand Rapids, Michigan • Chapel Hill, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 31, 2026, 5:25 PM EDT
Withdrawn Phase 2 Interventional

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

NCT00728000
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemcitabine, Oxaliplatin, Erlotinib
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

NCT01140607
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
Cabazitaxel (XRP6258)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
La Jolla, California • Loma Linda, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Results available

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

NCT04134936
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tafasitamab, Tafasitamab plus lenalidomide
Drug
Lead sponsor
MorphoSys AG
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Tucson, Arizona • Anaheim, California • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 31, 2026, 5:25 PM EDT
Completed No phase listed Observational Results available

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

NCT00851799
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir, Raltegravir, Darunavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

Pragmatic, Randomized Optimal Platelet and Plasma Ratios

NCT01545232
View directory record Official record
Conditions
Trauma
Interventions
1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clarity in Motion Phase-1 Perceptual Study of Speech Intelligibility

NCT07020728
View directory record Official record
Conditions
Healthy
Interventions
Solo: Unmasked Speech Stimuli, Raw: Fully masked speech--no motion stimuli, StatScrub: Extracted Speech--no motion stimuli, SlideSpch: Scrubbed Speech emitted from linearly moving speaker stimuli, SlideNoise: Speech Scrubbed from linearly moving and stationary noise stimuli, SlideMic: Stationary sources scrubbed from a linearly moving mic stimuli
Behavioral
Lead sponsor
Speech Technology and Applied Research Corp.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00005044
View directory record Official record
Conditions
Prostate Cancer
Interventions
Casodex, Eulexin, LHRH agonist, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2022
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Results available

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

NCT00044044
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
34
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 31, 2026, 5:25 PM EDT
Terminated Phase 1 Interventional

A Study of BTX-1188 in Subjects With Advanced Malignancies

NCT05144334
View directory record Official record
Conditions
Advanced Solid Tumor, Non Hodgkin Lymphoma, Acute Myeloid Leukemia
Interventions
BTX-1188
Drug
Lead sponsor
Biotheryx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Duarte, California • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Delayed Cord Clamping in VLBW Infants

NCT01222364
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Standard Cord Clamping, Delayed Cord Clamping
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
0 Minutes to 1 Minute
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000
U.S. locations
4
States / cities
Birmingham, Alabama • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 31, 2026, 5:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients

NCT01335230
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic, HCV Coinfection
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2015 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 3 Interventional

Bipolar II Depression: Lithium, SSRI, or the Combination

NCT00276965
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Sertraline, Lithium carbonate
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 31, 2026, 5:25 PM EDT
Completed Phase 4 Interventional Results available

A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia

NCT00386334
View directory record Official record
Conditions
Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
65 Years to 85 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
82
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 31, 2026, 5:25 PM EDT